Core-Shell Phase Column Increases Reproducibility
Phenomenex’s Kinetex F5 is a pentafluorophenyl propyl core-shell phase column designed to improve reproducibility and reduce method development time.
Phenomenex’s Kinetex F5 is a pentafluorophenyl propyl core-shell phase column designed to improve reproducibility and reduce method development time. A combination of polar and non-polar interactions including hydrogen bonding, electrostatic, hydrophobic, aromatic, and steric/planar mechanisms makes the column useful for high performance liquid chromatography (HPLC)/ultra high performance liquid chromatography (UHPLC) development work. The column allows for reversed phase, 2D-LC, hydrophilic interaction liquid chromatography, supercritical fluid chromatography, or 100% aqueous separation modes, while the fluorinated groups and carbon ring structure are ideal for methods that include halogenated, conjugated, or isomeric compounds.
The column is available in 2.6 and 1.7 μm particle sizes. The 2.6 μm version provides comparable performace to sub-2 μm particles for HPLC and UHPLC systems. The 1.7 μm column delivers 20% greater efficiency than fully-porous sub-2 μm products.
Phenomenex
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
August 2nd 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
August 2nd 2025In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
